Conditions: Neuroendocrine Carcinoma; Islet Cell Carcinoma
Interventions: Drug: RAD001; Drug: Octreotide Depot
Sponsors: M.D. Anderson Cancer Center; Novartis Pharmaceuticals
Completed
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
